S. Hillman

发表

Screening for lung cancer with low-dose spiral computed tomography.

S. Swensen, J. Jett, T. Hartman, 2000, American journal of respiratory and critical care medicine.

Screening for lung cancer with low-dose spiral computed tomography.

S. Swensen, J. Jett, T. Hartman, 2000, American journal of respiratory and critical care medicine.

A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1).

J. Jett, J. Sloan, S. Hillman, 2002, International journal of radiation oncology, biology, physics.

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.

E. Perez, J. Buckner, D. Sargent, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

E. Perez, J. Jett, S. Hillman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Why do oncologists prescribe--or not prescribe--conventional chemotherapy to geriatric patients with metastatic non-small cell lung cancer?

S. Hillman, K. Rowland, S. Dakhil, 2006, The journal of supportive oncology.

Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients.

B. Meyers, S. Mandrekar, S. Hillman, 2013, The Annals of thoracic surgery.

Impact of the COVID-19 Pandemic on Cancer Clinical Trials

S. Mandrekar, S. Hillman, J. Boughey, 2021, Annals of Surgical Oncology.

CT screening for lung cancer: five-year prospective experience.

Anne-Marie Sykes, Sumithra J Mandrekar, S. Swensen, 2005, Radiology.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

J. Buckner, D. Sargent, S. Hillman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study

J. Jett, S. Mandrekar, S. Hillman, 2007 .

Reply to M.A. Rosen et al

D. Sargent, S. Hillman, 2010 .

Reply to P. Prassopoulos et al

D. Sargent, S. Hillman, 2010 .

Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients

J. Jett, J. Sloan, S. Hillman, 2003, Supportive Care in Cancer.

What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

J. Buckner, D. Sargent, S. Mandrekar, 2008 .

Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial

Amita Sharma, S. Hillman, K. Hong, 2015, Cancer.

Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience

S. Mandrekar, S. Hillman, D. Zahrieh, 2022, Trials.

Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer: A North Central Cancer Treatment Group Study

E. Perez, J. Jett, S. Hillman, 2010, American journal of clinical oncology.

Statistical controversies in clinical research: Value of adverse events relatedness to study treatment analyses of data from randomized double-blind placebo-controlled clinical trials

S. Mandrekar, S. Hillman, C. Loprinzi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.

E. Perez, S. Hillman, R. Marks, 2004, Lung cancer.

Weekly Carboplatin and Paclitaxel in Elderly Non–Small-Cell Lung Cancer Patients (≥65 Years of Age): A Phase II North Central Cancer Treatment Group Study

E. Perez, J. Jett, S. Hillman, 2003, American journal of clinical oncology.

A Phase II NCCTG Study of Irinotecan and Docetaxel in Previously Treated Patients with Non-Small Cell Lung Cancer

J. Jett, S. Hillman, K. Rowland, 2006, Cancer investigation.

Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).

S. Hillman, R. Marks, J. Kugler, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

E. Perez, J. Jett, S. Mandrekar, 2008, Lung cancer.

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).

R. Govindan, S. Mandrekar, S. Hillman, 2022, JAMA oncology.

Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia

D. Sargent, S. Hillman, D. Ahlquist, 2008, Annals of Internal Medicine.

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.

C. Obasaju, J. Jett, S. Mandrekar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222

S. Hillman, K. Rowland, A. Jatoi, 2011, Cancer investigation.

Phase II NCCTG Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

J. Jett, S. Hillman, N. Foster, 2006, American journal of clinical oncology.

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

R. Govindan, J. Bradley, S. Mandrekar, 2021, Immunotherapy.

Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.

D. Heron, B. Meyers, S. Mandrekar, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.

J. Jett, S. Hillman, D. Northfelt, 2005, International journal of radiation oncology, biology, physics.

Long‐Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

J. Jett, S. Hillman, A. Tan, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.

S. Mandrekar, S. Hillman, U. Gatzemeier, 2011, Clinical lung cancer.

A prognostic model for advanced stage nonsmall cell lung cancer

J. Jett, S. Mandrekar, S. Hillman, 2006, Cancer.

Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials

P. Thall, S. Mandrekar, S. Hillman, 2020, Cancers.

A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non–Small-Cell Lung Cancer

J. Sloan, S. Hillman, R. Marks, 2003, American journal of clinical oncology.

The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial.

D. Heron, B. Meyers, S. Mandrekar, 2011, The Journal of thoracic and cardiovascular surgery.

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.

R. Arusell, J. Jett, S. Hillman, 2004, International journal of radiation oncology, biology, physics.

Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial.

Dwight E Heron, Sumithra J Mandrekar, D. Heron, 2015, The Journal of thoracic and cardiovascular surgery.

Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222

S. Hillman, K. Rowland, A. Jatoi, 2009, Cancer management and research.

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive‐stage small cell lung carcinoma

J. Jett, S. Hillman, R. Marks, 2003, Cancer.

A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer

S. Mandrekar, S. Hillman, S. Nair, 2010, Cancer.

Impact of disease progression date determination on progression‐free survival estimates in advanced lung cancer

S. Mandrekar, S. Hillman, D. Gandara, 2012, Cancer.

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

P. Jänne, R. Govindan, S. Mandrekar, 2020 .

PD-080 A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes

J. Jett, S. Mandrekar, S. Hillman, 2005 .

A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes

J. Jett, S. Mandrekar, S. Hillman, 2005 .

Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study.

D. Heron, B. Meyers, S. Mandrekar, 2011, The Journal of thoracic and cardiovascular surgery.

Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire.

Pamela S. Sinicrope, S. Hillman, A. Harris, 2014, World journal of gastroenterology.

Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials

Sumithra J. Mandrekar, Henry C. Pitot, Daniel J. Sargent, 2011, Clinical Cancer Research.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

S. Mandrekar, S. Hillman, R. Marks, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of the COVID-19 Pandemic on Cancer Clinical Trials

S. Mandrekar, S. Hillman, J. Boughey, 2021 .

Learning and support preferences of adult patients with cancer at a comprehensive cancer center.

S. Hillman, A. M. Dose, J. H. Chelf, 2002, Oncology nursing forum.

Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?

S. Hillman, B. Siegel, J. Shepard, 2011, AJR. American journal of roentgenology.

Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222

S. Hillman, K. Rowland, A. Jatoi, 2009 .

CMR-4547-Is social support associated with improved clinical

S. Hillman, K. Rowland, A. Jatoi, 2009 .

O-73 High dose, twice-daily thoracic radiotherapy (TRT) with daily chemotherapy in limited stage small cell lung cancer

J. Jett, J. Sloan, S. Hillman, 2003 .

O-68 Long term results of a phase III trial comparing once a day radiotherapy (qd RT) or twice a day radiotherapy (bid RT) in limited stage small cell lung cancer (LSCLC)

J. Jett, S. Hillman, J. Krook, 2003 .

Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials.

S. Mandrekar, S. Hillman, S. George, 2023, JAMA oncology.

Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?

S. Hillman, B. Siegel, J. Shepard, 2011, AJR. American journal of roentgenology.

Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial.

E. Perez, J. Buckner, D. Sargent, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.

S. Mandrekar, S. Hillman, U. Gatzemeier, 2011, Clinical lung cancer.